Published studies of anticoagulants in patients with sickle cell disease (SCD).
| Study . | Genotype . | No. of patients . | Therapy . | Randomized . | Duration . | Efficacy outcome measure and results . |
|---|---|---|---|---|---|---|
| Salvaggio et al51 (1963) | HbSS | 12 | Warfarin | No | 12–34 months | Modest decrease in frequency of pain episodes |
| Chaplin et al54 (1989) | HbSS | 4 | Heparin | No | 2–6 years | Reduced frequency of pain episodes |
| Wolters et al52 (1995) | HbSS | 6 | Acenocoumarol | No | 2 months | Reduced prothrombin fragment 1.2 |
| HbSC | 1 | |||||
| Schnog et al53 (2001) | HbSS | 14 | Acenocoumarol vs placebo | Yes | 14 weeks | Reduced markers of coagulation activation, but no reduction of pain episodes with active treatment |
| Hb C | 8 |
| Study . | Genotype . | No. of patients . | Therapy . | Randomized . | Duration . | Efficacy outcome measure and results . |
|---|---|---|---|---|---|---|
| Salvaggio et al51 (1963) | HbSS | 12 | Warfarin | No | 12–34 months | Modest decrease in frequency of pain episodes |
| Chaplin et al54 (1989) | HbSS | 4 | Heparin | No | 2–6 years | Reduced frequency of pain episodes |
| Wolters et al52 (1995) | HbSS | 6 | Acenocoumarol | No | 2 months | Reduced prothrombin fragment 1.2 |
| HbSC | 1 | |||||
| Schnog et al53 (2001) | HbSS | 14 | Acenocoumarol vs placebo | Yes | 14 weeks | Reduced markers of coagulation activation, but no reduction of pain episodes with active treatment |
| Hb C | 8 |